
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is poised for significant growth due to its pipeline of potential radiopharmaceuticals and its successful partnership with Regeneron to develop and commercialize radiopharma therapies targeting multiple solid tumors. This collaboration not only provides Telix with upfront funding and potential milestones/royalties, but also validates the use of radiopharmaceuticals in oncology. With a sum-of-parts valuation and potential market value of $6.66B, Telix has a positive outlook with risks including negative clinical results, delays in advancing pipeline candidates, regulatory approvals, competition, and long-term dilution risk.
Bears say
Telix Pharmaceuticals is currently generating most of its revenue from US sales of Illuccix, a prostate cancer imaging agent, and has a pipeline of potential radiopharmaceuticals in development. However, the upcoming regulatory milestones for TLX's PSMA imaging portfolio, as well as the resubmission of its NDA for Pixclara in the US and MAA in Europe and BLA for Zircaix in 1H26, create potential for incremental growth in the future. These developments, coupled with Telix's low sales multiple compared to its peers, suggest a negative outlook for its stock.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares